HP announced a new direct digital dispensing design for medical research that uses its inkjet technology that enables pharmaceutical companies to more efficiently develop better drugs through vastly more precise dispensing of dosages.
HP high-performance inkjet dispensing technology is now being used to speed the evaluation of how potential drug compounds impact biologic agents like cancer cells at very low concentrations. This new capability can help researchers significantly improve accuracy when evaluating drug safety and effectiveness, testing for drug interactions and developing new drugs.
HP's methodology also can decrease expensive labware and biological fluid waste associated with complex, conventional testing methods, reducing research costs. The process also can improve productivity by eliminating many time-consuming and tedious steps in the drug discovery process.
"Current methods for drug dosing rely on costly manual or automated processes, which're time consuming, error prone and wasteful," said Kathy Tobin, HP. "Our inkjet "scalable printing technology" can precisely and rapidly dispense droplets that've one-third the width of a human hair, offering pharmaceutical companies the high-performance dispensing necessary to streamline critical R&D processes and speed drug discovery research."
The inkjets can dispense compounds drop-by-drop in measurements as small as 20 picoliters with a variation coefficient less than 8%, at a speed of less than 30 seconds per titration.